Sign In
Buy ZVRA
$13.00
+0.350 (+2.77%)
At Close: Jun 23, 2026
Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility
07:30am, Wednesday, 10'th Apr 2024
CELEBRATION, Fla., April 10, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that it has entered into
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
06:20pm, Thursday, 04'th Apr 2024
NEW YORK , April 4, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zevra Therapeutics, Inc. ("Zevra" or the "Company") (NASDAQ: ZVRA). Such investors are advised
Zevra Therapeutics, Inc. (ZVRA) Q4 2023 Earnings Call Transcript
10:25pm, Thursday, 28'th Mar 2024
Zevra Therapeutics, Inc. (ZVRA) Q4 2023 Earnings Call Transcript
Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
04:32pm, Thursday, 28'th Mar 2024
Launch of OLPRUVA® underway Topline results from KP1077 phase 2 study demonstrate clinically meaningful benefits for key IH symptoms Q4 2023 net revenue of $13.2M, and FY 2023 net revenue of $27.5M C
Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia
04:30pm, Tuesday, 26'th Mar 2024
KP1077 demonstrates clinically meaningful benefits for key IH symptoms Top-line data provide key information for the design of a Phase 3 study CELEBRATION, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- Zev
Zevra Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
04:30pm, Monday, 25'th Mar 2024
CELEBRATION, Fla., March 25, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced that it will participate
Will Zevra Therapeutics (ZVRA) Report Negative Earnings Next Week? What You Should Know
11:01am, Thursday, 21'st Mar 2024
Zevra Therapeutics, Inc. (ZVRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results on March 28, 2024
07:30am, Monday, 18'th Mar 2024
CELEBRATION, Fla., March 18, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company) a rare disease therapeutics company, today announced that it will host a confere
Zevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol as a Treatment for Niemann-Pick Disease Type C
07:30am, Monday, 04'th Mar 2024
The new Prescription Drug User Fee Act (PDUFA) action date set by the FDA is September 21, 2024 CELEBRATION, Fla., March 04, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra
Zevra Therapeutics to Participate at Upcoming Investor Conferences
07:30am, Wednesday, 28'th Feb 2024
CELEBRATION, Fla., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced that Neil F. McFarlane, P
Zevra Therapeutics (ZVRA) Soars 6.6%: Is Further Upside Left in the Stock?
04:50am, Thursday, 15'th Feb 2024
Zevra Therapeutics (ZVRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength d
Zevra Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
07:30am, Tuesday, 06'th Feb 2024
CELEBRATION, Fla., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced that it will present at t
Zevra Therapeutics, Inc. (ZVRA) Q3 2023 Earnings Call Transcript
12:36am, Saturday, 11'th Nov 2023
Zevra Therapeutics, Inc. (NASDAQ:ZVRA ) Q3 2023 Earnings Conference Call November 7, 2023 8:00 AM ET Company Participants Nichol Ochsner - Vice President of Investor Relations Neil McFarlane - Preside
Zevra Therapeutics to Report Third Quarter 2023 Results on November 7, 2023, at 8:00 a.m. ET
07:30am, Tuesday, 31'st Oct 2023
CELEBRATION, Fla., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company) a rare disease therapeutics company, today announced that it will host a conferen
Zevra Therapeutics to Present at the 52nd Child Neurology Society Annual Meeting
07:30am, Thursday, 05'th Oct 2023
Presentation to focus on the arimoclomol program for the treatment of Niemann-Pick Disease type C and related early access programs
